Jeremy Mason
Overview
Explore the profile of Jeremy Mason including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
55
Citations
2510
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Murgoitio-Esandi J, Tessone D, Naghdloo A, Shishido S, Zhang B, Xu H, et al.
bioRxiv
. 2025 Feb;
PMID: 39975209
The use of liquid biopsies in the detection, diagnosis and treatment monitoring of different types of cancers and other diseases often requires identifying and enumerating instances of analytes that are...
2.
Waldron R, Wang R, Shishido S, Lugea A, Ibrahim A, Mason J, et al.
Cancer Lett
. 2025 Feb;
614:217546.
PMID: 39952600
Metastatic pancreatic ductal adenocarcinoma (PDAC) is a deadly disease with limited efficacious therapeutic options. Recent investigations have provided proof of concept that circulating tumor cells (CTCs) are reduced by purification...
3.
Shishido S, Marvit A, Pham D, Luo T, Xu L, Mason J, et al.
Cancers (Basel)
. 2024 Nov;
16(22).
PMID: 39594700
Background/objectives: Up to 30% of patients with breast cancers will develop brain or leptomeningeal metastases, and this risk is especially high with HER2-positive cancers. For patients with central nervous system...
4.
Shishido S, Suresh D, Courcoubetis G, Ye B, Lin E, Mason J, et al.
BJC Rep
. 2024 Nov;
2(1):47.
PMID: 39516545
Background: Cancer becomes lethal as it spreads from the primary site to the rest of the body. Circulating tumor cells (CTCs) are biomarkers of disease progression and have been associated...
5.
Resnick K, Shah A, Mason J, Kuhn P, Nieva J, Shishido S
Thorac Cancer
. 2024 Sep;
15(29):2100-2109.
PMID: 39233479
Background: Lung cancer screening with low-dose computed tomography (CT) scans (LDCT) has reduced mortality for patients with high-risk smoking histories, but it has significant limitations: LDCT screening implementation remains low,...
6.
Spielmann N, Miller G, Oprea T, Hsu C, Fobo G, Frishman G, et al.
Nat Cardiovasc Res
. 2024 Aug;
1(2):157-173.
PMID: 39195995
Clinical presentation of congenital heart disease is heterogeneous, making identification of the disease-causing genes and their genetic pathways and mechanisms of action challenging. By using in vivo electrocardiography, transthoracic echocardiography...
7.
Bai L, Courcoubetis G, Mason J, Hicks J, Nieva J, Kuhn P, et al.
Discov Oncol
. 2024 May;
15(1):142.
PMID: 38700626
In the United States, lung cancer is the second most common type of cancer with non-small cell lung cancer (NSCLC) encompassing around 85% of total lung cancer cases. Late-stage patients...
8.
Mahmoodifar S, Pangal D, Neman J, Zada G, Mason J, Salhia B, et al.
J Neurooncol
. 2024 Apr;
167(3):501-508.
PMID: 38563856
Objective: Brain metastases (BM) are associated with poor prognosis and increased mortality rates, making them a significant clinical challenge. Studying BMs can aid in improving early detection and monitoring. Systematic...
9.
Ghoreifi A, Shishido S, Sayeed S, Courcoubetis G, Huang A, Schuckman A, et al.
Urol Oncol
. 2024 Feb;
42(4):118.e9-118.e17.
PMID: 38383240
Objectives: To assess the efficacy of blood-based liquid biopsy in the diagnosis, surveillance, and prognosis of upper tract urothelial carcinoma (UTUC). Methods And Materials: In this prospective study, peripheral blood...
10.
Shishido S, Lin E, Nissen N, Courcoubetis G, Suresh D, Mason J, et al.
NPJ Precis Oncol
. 2024 Feb;
8(1):36.
PMID: 38360856
Pancreatic ductal adenocarcinoma (PDAC) has a five-year survival rate of less than 10% due to its late diagnosis, rapid metastasis, and chemotherapeutic resistance. For a small proportion (10-20%) of early-stage...